ArticleMolecular cancer2026

An orally bioavailable pan-αv/α5β1 integrin antagonist prevents aggressive prostate cancer progression via suppressing both oncogenic signals and CD47-mediated immune escape.

Yanlun Gu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.